Stem Cell Therapy in Wound Care: Current Status and Future

Stem Cell Therapy in Wound Care: Separating Science from Speculation

Stem cell therapy is one of the most promising — and most overhyped — areas in wound care. The biological rationale is compelling: stem cells can differentiate into multiple cell types, secrete growth factors that stimulate tissue repair, modulate inflammation, and recruit additional reparative cells to the wound site. Early clinical results are encouraging. But the gap between laboratory results and approved, evidence-based clinical products remains wide. For wound care clinicians, the challenge is distinguishing between what is scientifically validated, what is commercially available, what is FDA-regulated, and what is marketing dressed up as medicine.

Types of Stem Cells Relevant to Wound Healing

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells are the most extensively studied stem cell type in wound healing. MSCs can be isolated from bone marrow, adipose tissue, umbilical cord blood, Wharton's jelly, placental tissue, and amniotic fluid. They have the capacity to differentiate into fibroblasts, endothelial cells, and keratinocytes — the primary cell types needed for wound repair.

However, current evidence suggests that the primary mechanism by which MSCs promote healing is not differentiation into wound cells but rather paracrine signaling. MSCs secrete a complex mixture of growth factors (VEGF, PDGF, TGF-beta, HGF, EGF), anti-inflammatory cytokines (IL-10, TSG-6), and extracellular vesicles (exosomes) that collectively:

Stimulate angiogenesis
Reduce inflammation and shift macrophages from M1 to M2 phenotype
Recruit endogenous stem cells and progenitor cells to the wound
Inhibit fibrosis and scar formation
Modulate MMP activity

Adipose-Derived Stem Cells (ADSCs)

ADSCs are a subtype of mesenchymal stem cells harvested from adipose tissue, typically via liposuction. They are of particular clinical interest because they are abundant (adipose tissue yields approximately 500 times more stem cells per gram than bone marrow), accessible through minimally invasive harvest, and demonstrate strong angiogenic and anti-inflammatory properties. Several clinical trials have investigated autologous ADSC injection for chronic wounds, particularly diabetic foot ulcers and radiation injuries.

Induced Pluripotent Stem Cells (iPSCs)

iPSCs are adult cells reprogrammed to an embryonic-like state. They can theoretically differentiate into any cell type, offering broader regenerative potential than MSCs. However, iPSC-based wound therapies remain in preclinical stages due to concerns about tumorigenicity, manufacturing complexity, and regulatory hurdles.

Epidermal Stem Cells

Epidermal stem cells reside in the basal layer of the epidermis and in hair follicle bulge regions. They are responsible for normal skin renewal and contribute to wound re-epithelialization. Cultured epithelial autograft (CEA) — sheets of autologous keratinocytes grown from patient skin biopsies — is one of the earliest stem cell-derived wound therapies and has been in clinical use for severe burns since the 1980s.

What Is Currently Available and FDA-Regulated

Cellular and Tissue-Based Products (CTPs)

The regulatory landscape for stem cell-containing wound products is complex and frequently misunderstood. The FDA regulates these products under Section 361 of the Public Health Service Act (for minimally manipulated human cells, tissues, and cellular and tissue-based products, or HCT/Ps) or as biologics requiring premarket approval.

Products regulated under Section 361 must meet four criteria: minimal manipulation, homologous use, no combination with drugs or devices, and no systemic effect. Many amniotic membrane and placental tissue products used in wound care are marketed under this pathway. They may contain growth factors, extracellular matrix components, and residual stem cells, but they are not marketed as stem cell therapies and their stem cell content (if any) varies significantly between products.

Products with Biological Evidence

Several product categories contain stem cell-relevant biology:

Dehydrated human amnion/chorion membrane (dHACM) — products like EpiFix and Grafix are derived from human placental tissue and contain growth factors, cytokines, and extracellular matrix components. Grafix is a cryopreserved product that retains viable cells including MSCs. Clinical trials have demonstrated improved healing rates in diabetic foot ulcers compared to standard care.

Autologous platelet-rich plasma (PRP) — while not a stem cell product, PRP concentrates platelets and their growth factor cargo. It is prepared from the patient's own blood and applied to the wound. Evidence supports its use as an adjunct in chronic wounds, though it does not contain stem cells.

Cultured epithelial autograft (CEA) — Epicel is an FDA-approved cultured epidermal autograft for severe burns. Keratinocytes are harvested from a patient skin biopsy, expanded in culture, and applied as sheets. This is one of the few true cell-therapy products with long-standing FDA approval for wound indications.

What Is Not (Legally) Available

Multiple clinics market stem cell injections for chronic wounds, arthritis, and other conditions using autologous bone marrow concentrate or adipose-derived cells that have been more than minimally manipulated. The FDA has taken enforcement action against several of these practices. Clinicians should be aware that:

Autologous stem cell therapy that involves more than minimal manipulation requires an investigational new drug (IND) application or biologics license application (BLA)
"Stem cell clinics" operating outside FDA regulatory frameworks may expose patients to safety risks including infection, tumor formation, and ineffective treatment
Insurance coverage for unapproved stem cell therapies is essentially nonexistent

For current information on growth factor-based therapies that have a more established regulatory path, see our guide on growth factors and biologics in wound care.

Current Research and Clinical Trials

Diabetic Foot Ulcers

Multiple phase I/II clinical trials have investigated MSC therapy for diabetic foot ulcers — both as direct wound injection and as cell-seeded scaffolds. Results have generally shown improved healing rates and faster time to closure compared to standard care, but sample sizes remain small and long-term outcomes data are limited.

Venous Leg Ulcers

A smaller body of research has investigated MSC therapy for venous leg ulcers. The anti-inflammatory paracrine effects of MSCs are theoretically well-suited to the inflammatory microenvironment of venous ulcers, but clinical data remain preliminary.

Radiation Wounds

Adipose-derived stem cell therapy has shown particular promise for late radiation injuries. The combination of anti-inflammatory, pro-angiogenic, and anti-fibrotic effects addresses multiple aspects of radiation tissue damage. Several case series have reported significant improvement in chronic radiation wounds that had failed conventional therapy.

Exosome-Based Therapies

An emerging research area focuses on MSC-derived exosomes — nanoscale vesicles that carry the paracrine signaling molecules without the cells themselves. Exosome-based therapies could potentially offer the regenerative benefits of MSC therapy with simpler manufacturing, storage, and regulatory pathways. However, these products remain in preclinical and early clinical stages.

What Clinicians Should Know

Evidence-Based Practice Perspective

The evidence base for stem cell therapy in wound care, as reviewed through an evidence-based practice lens, supports cautious optimism but not routine clinical adoption outside of clinical trials and FDA-approved products. Clinicians should:

Use FDA-approved or 361-regulated products when the evidence supports their use for specific wound types
Refer patients to clinical trials when conventional therapy has failed and stem cell therapy is being investigated for their wound type
Not recommend unregulated stem cell clinic treatments to patients
Stay current with the rapidly evolving regulatory landscape

The Realistic Timeline

Stem cell therapy will likely become a standard part of wound care — but not imminently. The timeline for widespread adoption depends on:

Completion of phase III clinical trials establishing efficacy and safety
Manufacturing standardization that produces consistent, scalable products
Regulatory clarity on the pathway for cell-based wound products
Reimbursement policy development by CMS and commercial payers
Cost reduction that makes therapy accessible beyond specialized centers

Key Takeaways

Mesenchymal stem cells promote wound healing primarily through paracrine signaling (secreting growth factors, anti-inflammatory cytokines, and exosomes) rather than differentiating into wound repair cells.
FDA-regulated products containing stem cell-relevant biology (dHACM, cryopreserved placental tissue, cultured epithelial autograft) are currently available and have clinical evidence supporting their use in specific wound types.
Unregulated stem cell clinics operate outside FDA frameworks and may expose patients to safety risks — clinicians should direct patients toward clinical trials or approved products.
MSC-derived exosome therapy is a promising research direction that could simplify manufacturing and regulatory pathways while preserving paracrine regenerative benefits.
Routine clinical adoption of dedicated stem cell wound therapy awaits completion of phase III trials, manufacturing standardization, and reimbursement policy development.